Comparative Pharmacology
Head-to-head clinical analysis: PROCARDIA XL versus TAZTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCARDIA XL versus TAZTIA XT.
PROCARDIA XL vs TAZTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
30-90 mg orally once daily, extended-release tablet.
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker